LncRNA UCA1 in anti-cancer drug resistance

被引：134
|
作者：
Wang, Haohao [1 ,2 ]
Guan, Zhonghai [1 ]
He, Kuifeng [1 ,2 ]
Qian, Jiong [1 ]
Cao, Jiang [3 ]
Teng, Lisong [1 ,2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Ctr Canc, Hangzhou, Zhejiang, Peoples R China
[2] Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Clin Res Ctr, Hangzhou, Zhejiang, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 38期
基金：
中国国家自然科学基金;
关键词：
long non-coding RNA; UCA1; chemoresistance; cancer; LONG NONCODING RNA; CARCINOMA-ASSOCIATED; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; ENHANCES TAMOXIFEN RESISTANCE; TYROSINE KINASE INHIBITORS; BREAST-CANCER; MULTIDRUG-RESISTANCE; POOR-PROGNOSIS; MOLECULAR-MECHANISMS;
D O I：
10.18632/oncotarget.18344
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.
引用
收藏
页码：64638 / 64650
页数：13
相关论文
共 50 条
  • [1] Crosstalk between the lncRNA UCA1 and microRNAs in cancer
    Xuan, Wei
    Yu, Hongyu
    Zhang, Xiaoling
    Song, Dandan
    FEBS LETTERS, 2019, 593 (15) : 1901 - 1914
  • [2] The prognostic value and mechanisms of lncRNA UCA1 in human cancer
    Yao, Fei
    Wang, Qiang
    Wu, Qingming
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7685 - 7696
  • [3] H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy
    Zhong, Chenming
    Xie, Zijun
    Duan, Shiwei
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (10):
  • [4] UCA1 lncRNA in metastases and prognosis
    Song, Wei
    Wang, Kai
    Zou, Shu-Bing
    PANMINERVA MEDICA, 2017, 59 (03) : 278 - 279
  • [5] Molecular chess? Hallmarks of anti-cancer drug resistance!
    Cree, Ian A.
    Charlton, Peter
    BMC CANCER, 2017, 17
  • [6] Up-regulation of LncRNA UCA1 by TGF-β promotes doxorubicin resistance in breast cancer cells
    Wo, Like
    Zhang, Bei
    You, Xiongbin
    Hu, Yuanyuan
    Gu, Zhenqi
    Zhang, Mengning
    Wang, Qi
    Lv, Zhengyi
    Zhao, Hong
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2022, 44 (04) : 492 - 499
  • [7] UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis
    Wang, Junrong
    Ye, Cong
    Liu, Junbao
    Hu, Yubo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 501 (04) : 1034 - 1040
  • [8] Expression of lncRNA UCA1 in ovarian cancer and its clinical significance
    Qiu, Y. R.
    Zhao, M. Y.
    Sun, L.
    Yang, B. C.
    Hei, K. W.
    Du, X.
    Li, Y. M.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2017, 38 (02) : 191 - 195
  • [9] Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer
    Avgeris, Margaritis
    Tsilimantou, Anastasia
    Levis, Panagiotis K.
    Rampias, Theodoros
    Papadimitriou, Maria-Alexandra
    Panoutsopoulou, Konstantina
    Stravodimos, Konstantinos
    Scorilas, Andreas
    CARCINOGENESIS, 2019, 40 (08) : 965 - 974
  • [10] LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway
    Zhang, Meiting
    Zhao, Yi
    Zhang, Youli
    Wang, Dawei
    Gu, Shuming
    Feng, Wen
    Peng, Wanxin
    Gong, Aihua
    Xu, Min
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (05): : 1770 - 1782
12345